Alkermes plc announced today that management will participate in a fireside chat presentation at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference on Thursday, Sept. 26, 2024 at 9 ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit at 11:00 a.m. Eastern Time on Thursday, September 26, 2024.

Neurocrine Biosciences, Inc. (NBIX) stock saw a decline, ending the day at $119.85 which represents a decrease of $-2.46 or -2.01% from the prior close of $122.31. The stock opened at $123 and touched ...

GC Therapeutics claims it can create off-the-shelf therapies from induced pluripotent stem cells faster and simpler than current methods.

Selection of the development candidate triggered a $3 million milestone payment to Voyager, which the Company expects to receive in the fourth quarter of 2024. Voyager is eligible to receive ...

Voyager Therapeutics Inc. has announced the selection of a development candidate in a gene therapy program for the treatment of an undisclosed neurological disease under its collaboration with ...

We recently compiled a list of the 10 Best Aggressive Growth Stocks to Buy According to Hedge Funds. In this article, we are ...

Neurocrine Biosciences announced that its ERUDITE Phase 2 trial for luvadaxistat failed to meet its primary endpoint in ...

BMO Capital Markets analyst Evan Seigerman said luvadaxistat’s inconsistencies between mid-stage trials raise questions about ...

Neurocrine Biosciences has reported that its Phase II ERUDITE clinical trial of luvadaxistat did not achieve its primary ...

Neurocrine Biosciences’ schizophrenia program pivot has failed. | Neurocrine Biosciences’ schizophrenia program pivot has ...

Rich nations have millions of mpox vaccine doses while Africa faces severe shortages amid a growing outbreak. Moderna ...